Search

Your search keyword '"Riester, Markus"' showing total 121 results

Search Constraints

Start Over You searched for: Author "Riester, Markus" Remove constraint Author: "Riester, Markus" Database Unpaywall Remove constraint Database: Unpaywall
121 results on '"Riester, Markus"'

Search Results

1. Supplemental Figure S6 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance

2. Supplemental Figure S1 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance

3. Supplemental Figure S7 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance

4. Supplemental Figure S5 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance

5. Supplemental Figure S2 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance

6. Supplemental Figure S5 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance

7. Supplemental Figure S4 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance

8. Supplemental Figure S8 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance

9. Supplemental Figure S3 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance

10. Supplemental Figure S2 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance

11. Data from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance

12. Supplemental Figure S7 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance

13. Supplemental Figure and Table Legends from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance

14. Data from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance

15. Supplemental Figure S3 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance

16. Supplemental Figure and Table Legends from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance

17. Supplemental Tables 1 - 12 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance

18. Supplemental Figure S6 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance

19. Supplemental Figure S4 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance

20. Supplemental Tables 1 - 12 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance

21. Supplemental Figure S8 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance

22. Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance

23. Data from JAK–STAT Pathway Activation in Malignant and Nonmalignant Cells Contributes to MPN Pathogenesis and Therapeutic Response

24. Data from JAK–STAT Pathway Activation in Malignant and Nonmalignant Cells Contributes to MPN Pathogenesis and Therapeutic Response

25. Supplementary Figures 1 - 15, Tables 1 - 2 from JAK–STAT Pathway Activation in Malignant and Nonmalignant Cells Contributes to MPN Pathogenesis and Therapeutic Response

26. Supplementary Figures 1 - 15, Tables 1 - 2 from JAK–STAT Pathway Activation in Malignant and Nonmalignant Cells Contributes to MPN Pathogenesis and Therapeutic Response

27. Data from Software for the Integration of Multiomics Experiments in Bioconductor

28. Supplementary Figures 7 - 14, Tables 3 - 7 from Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma

29. Supplementary Figure Legends from Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma

30. Data from Software for the Integration of Multiomics Experiments in Bioconductor

33. Supplementary Data from Multiomic Analysis of Subtype Evolution and Heterogeneity in High-Grade Serous Ovarian Carcinoma

35. Supplementary Figures 1 - 5, Tables 1 - 2 from Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma

36. Supplementary Figure 6 from Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma

37. Data from Multiomic Analysis of Subtype Evolution and Heterogeneity in High-Grade Serous Ovarian Carcinoma

38. Supplementary Figures 15 - 17, Table 8 from Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma

39. Supplementary Figures 1 - 5, Tables 1 - 2 from Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma

40. Data from Multiomic Analysis of Subtype Evolution and Heterogeneity in High-Grade Serous Ovarian Carcinoma

41. Supplementary Data from Multiomic Analysis of Subtype Evolution and Heterogeneity in High-Grade Serous Ovarian Carcinoma

42. Supplementary Figures 15 - 17, Table 8 from Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma

45. Supplementary Figure Legends from Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma

46. Supplementary Figure 6 from Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma

47. Supplementary Figures 7 - 14, Tables 3 - 7 from Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma

49. A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors

Catalog

Books, media, physical & digital resources